Last reviewed · How we verify
Azithromycin 1 gram
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Pharyngitis/tonsillitis.
At a glance
| Generic name | Azithromycin 1 gram |
|---|---|
| Also known as | Zithromax |
| Sponsor | ActivBiotics Pharma, LLC |
| Drug class | Macrolide antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 2 |
Mechanism of action
This action prevents the formation of peptide bonds, ultimately inhibiting bacterial growth and replication. Azithromycin is a macrolide antibiotic that is effective against a wide range of Gram-positive and Gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Pharyngitis/tonsillitis
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (PHASE4)
- Azithromycin and Ampicillin for Late PPROM (PHASE4)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension (PHASE3)
- Azithromycin for Meibomian Gland Disease (PHASE4)
- Single Dose Azithromycin to Prevent Cholera in Children (PHASE2)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term (EARLY_PHASE1)
- Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin 1 gram CI brief — competitive landscape report
- Azithromycin 1 gram updates RSS · CI watch RSS
- ActivBiotics Pharma, LLC portfolio CI